Phase I evaluation of telatinib, a VEGF receptor tyrosine kinase inhibitor, in combination with bevacizumab in subjects with advanced solid tumors

Autor: Langenberg, M.H.G., Witteveen, P.O., Roodhart, J., Lolkema, M.P., Verheul, H.M.W., Mergui-Roelvink, M., Brendel, E., Krätzschmar, J., Loembé, B., Nol-Boekel, A., Christensen, O., Schellens, J.H.M., Voest, E.E. ^*

Publikováno v: In Annals of Oncology November 2011 22(11):2508-2515

Phase II trial with ISIS 5132 in patients with small-cell (SCLC) and non-small cell (NSCLC) lung cancer. A European Organization for Research and Treatment of Cancer (EORTC) Early Clinical Studies Group report

Autor: Coudert, B, Anthoney, A, Fiedler, W, Droz, J.P, Dieras, V, Borner, M, Smyth, J.F, Morant, R, de Vries, M.J, Roelvink, M, Fumoleau, P

Publikováno v: In European Journal of Cancer 2001 37(17):2194-2198

Activity and toxicity of GI147211 in breast, colorectal and non-small-cell lung cancer patients: An EORTC—ECSG phase II clinical study

Autor: Gamucci, T. ^*, Paridaens, R., Heinrich, B., Schellens, J.H., Pavlidis, N., Verweij, J., Sessa, C., Kaye, S., Roelvink, M., Wanders, J., Hanauske, A.

Publikováno v: In Annals of Oncology July 2000 11(7):793-797

A Phase 1 Dose-Escalation Study of Low-Dose Metronomic Treatment With Novel Oral Paclitaxel Formulations in Combination With Ritonavir in Patients With Advanced Solid Tumors.

Autor: de Weger VA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Vermunt MAC; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Stuurman FE; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Burylo AM; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Damoiseaux D; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Hendrikx JJMA; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Nuclear Medicine, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Sawicki E; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, The Netherlands., Moes JJ; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Huitema ADR; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Pharmacy, University Medical Center Utrecht, Utrecht University, The Netherlands., Nuijen B; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Rosing H; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Mergui-Roelvink M; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Beijnen JH; Department of Pharmacy & Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Modra Pharmaceuticals BV, Amsterdam, The Netherlands.; Department of Pharmaceutical Sciences, Utrecht University, Utrecht, The Netherlands., Marchetti S; Division of Clinical Pharmacology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.

Publikováno v: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2021 Jun; Vol. 10 (6), pp. 607-621. Date of Electronic Publication: 2020 Oct 05.

Documentary Analysis of Hypericum perforatum (St. John's Wort) and Its Effect on Depressive Disorders.

Autor: Otero, María Carolina¹ (AUTHOR) maria.otero@unab.cl, Ceric, Francisco² (AUTHOR) fceric@udd.cl, Miranda-Rojas, Sebastián^3,4 (AUTHOR) sebastian.miranda@unab.cl, Carreño, Carolina⁵ (AUTHOR), Escares, Rachelly⁵ (AUTHOR), Escobar, María José⁵ (AUTHOR), Saracini, Chiara⁶ (AUTHOR), Atala, Cristian⁷ (AUTHOR), Ramírez-Barrantes, Ricardo⁸ (AUTHOR) ricardo.ramirez@unab.cl, Gordillo-Fuenzalida, Felipe⁹ (AUTHOR) fgordillo@ucm.cl

Publikováno v: Pharmaceuticals (14248247). Dec2024, Vol. 17 Issue 12, p1625. 18p.